TVTX Q3 2023 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M-30.7% YoY

Gross Profit

$36M96.5% margin

Operating Income

-$93M-249.6% margin

Net Income

$151M406.3% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

+15.2%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$833M

Total Liabilities

$553M

Stockholders' Equity

$280M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$53M	-30.7%
Gross Profit	$36M	$52M	-30.9%
Operating Income	-$93M	-$65M	-42.5%
Net Income	$151M	-$70M	+316.4%

Revenue Segments

Active Pharmaceutical Ingredient

$3M51%

License

$3M49%